Loading candles…
Akums Drugs and Pharmaceuticals Limited was incorporated in 2004 and operates as a pharmaceutical contract development and manufacturing organization (CDMO). The company provides a range of pharmaceutical products and services including formulation development, bio-equivalence studies, manufacturing, and regulatory compliance. Serving both the Indian market and over 70 other countries, Akums is active in the pharmaceutical industry and is recognized as a dominant player within the Indian pharmaceutical CDMO sector. It caters to major domestic and international pharmaceutical companies. The company does not have any publicly noted subsidiaries, founders, or listings on stock exchanges.
| Date |
|---|
| Intimation | Board Meeting Intimation- Recommendation of final dividend, if any, for the F.Y. 2025-26 | 14 May 2026 |
| Audited Results - Q4 & FY26 | Board Meeting Intimation for approval of the audited (Standalone & Consolidated) Financial Results for the quarter and financial year ended on 31st March, 2026. | 14 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 13 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 13 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 8 Aug 2025 |
| Unaudited Results - Q4 & FY25 | To consider and approve the Un-audited (Standalone & Consolidated) Financial Results for the quarter ended on 31st March, 2025 and Audited (Standalone & Cons… | 26 May 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.